184 related articles for article (PubMed ID: 22157557)
1. Management of neuroendocrine tumors of unknown origin.
Polish A; Vergo MT; Agulnik M
J Natl Compr Canc Netw; 2011 Dec; 9(12):1397-402; quiz 1403. PubMed ID: 22157557
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
Yang Z; Klimstra DS; Hruban RH; Tang LH
Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
[TBL] [Abstract][Full Text] [Related]
3. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.
Pavel M; Baudin E; Couvelard A; Krenning E; Öberg K; Steinmüller T; Anlauf M; Wiedenmann B; Salazar R;
Neuroendocrinology; 2012; 95(2):157-76. PubMed ID: 22262022
[No Abstract] [Full Text] [Related]
4. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?
Catena L; Bichisao E; Milione M; Valente M; Platania M; Pusceddu S; Ducceschi M; Zilembo N; Formisano B; Bajetta E
Tumori; 2011; 97(5):564-7. PubMed ID: 22158484
[TBL] [Abstract][Full Text] [Related]
5. Update on the management of neuroendocrine hepatic metastases.
Madoff DC; Gupta S; Ahrar K; Murthy R; Yao JC
J Vasc Interv Radiol; 2006 Aug; 17(8):1235-49; quiz 1250. PubMed ID: 16923972
[TBL] [Abstract][Full Text] [Related]
6. The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.
Koo J; Zhou X; Moschiano E; De Peralta-Venturina M; Mertens RB; Dhall D
Endocr Pathol; 2013 Dec; 24(4):184-90. PubMed ID: 24037217
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary Site.
Berner AM; Pipinikas C; Ryan A; Dibra H; Moghul I; Webster A; Luong TV; Thirlwell C
Neuroendocrinology; 2020; 110(7-8):563-573. PubMed ID: 31658461
[TBL] [Abstract][Full Text] [Related]
8. Problems with the diagnosis of metastatic neuroendocrine neoplasms. Which diagnostic criteria should we use to determine tumor origin and help guide therapy?
Koo J; Dhall D
Semin Diagn Pathol; 2015 Nov; 32(6):456-68. PubMed ID: 26573790
[TBL] [Abstract][Full Text] [Related]
9. [Neuroendocrine Tumors].
Jantze A; Haller C; Delaloye R
Praxis (Bern 1994); 2016 Jan; 105(1):7-12; quiz 13-4. PubMed ID: 26732711
[No Abstract] [Full Text] [Related]
10. Current concepts in the diagnosis and management of neuroendocrine neoplasms of unknown primary origin.
Alexandraki KI; Tsoli M; Kyriakopoulos G; Angelousi A; Nikolopoulos G; Kolomodi D; Kaltsas GA
Minerva Endocrinol; 2019 Dec; 44(4):378-386. PubMed ID: 30991795
[TBL] [Abstract][Full Text] [Related]
11. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Wolin EM
Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease.
Hendifar AE; Marchevsky AM; Tuli R
J Thorac Oncol; 2017 Mar; 12(3):425-436. PubMed ID: 27890494
[TBL] [Abstract][Full Text] [Related]
13. Management of peritoneal metastasis from neuroendocrine tumors.
Au JT; Levine J; Aytaman A; Weber T; Serafini F
J Surg Oncol; 2013 Nov; 108(6):385-6. PubMed ID: 24142576
[No Abstract] [Full Text] [Related]
14. Neuroendocrine Merkel cell nodal carcinoma of unknown primary site: management and outcomes of a rare entity.
Kotteas EA; Pavlidis N
Crit Rev Oncol Hematol; 2015 Apr; 94(1):116-21. PubMed ID: 25573607
[TBL] [Abstract][Full Text] [Related]
15. Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
Van Eeden S; Quaedvlieg PF; Taal BG; Offerhaus GJ; Lamers CB; Van Velthuysen ML
Hum Pathol; 2002 Nov; 33(11):1126-32. PubMed ID: 12454818
[TBL] [Abstract][Full Text] [Related]
16. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?
Santhanam P; Chandramahanti S; Kroiss A; Yu R; Ruszniewski P; Kumar R; Taïeb D
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1144-55. PubMed ID: 25771906
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
18. [Digestive neuroendocrine tumors].
de Mestier L; Deguelte-Lardière S; Brixi H; Kianmanesh R; Cadiot G
Rev Med Interne; 2016 Aug; 37(8):551-60. PubMed ID: 26897113
[TBL] [Abstract][Full Text] [Related]
19. [Left supraclavicular adenopathy with a neuroendocrine pattern of unknown cause: prostatic carcinoma metastasis].
Fernández Borrell A; Peinado Ibarra F; Gómez Sancha F; Teba del Pino F; Minguez Martínez R; Morato Robert P; Arellano Gañan R; Romero Tejada JC; Pereira Sanz I
Actas Urol Esp; 1999; 23(7):603-8. PubMed ID: 10488615
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Shah MH; Goldner WS; Benson AB; Bergsland E; Blaszkowsky LS; Brock P; Chan J; Das S; Dickson PV; Fanta P; Giordano T; Halfdanarson TR; Halperin D; He J; Heaney A; Heslin MJ; Kandeel F; Kardan A; Khan SA; Kuvshinoff BW; Lieu C; Miller K; Pillarisetty VG; Reidy D; Salgado SA; Shaheen S; Soares HP; Soulen MC; Strosberg JR; Sussman CR; Trikalinos NA; Uboha NA; Vijayvergia N; Wong T; Lynn B; Hochstetler C
J Natl Compr Canc Netw; 2021 Jul; 19(7):839-868. PubMed ID: 34340212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
